ArticleGeburtshilfe und Frauenheilkunde2012
Breast Cancer: State of the Art and New Findings.
Article in Geburtshilfe und Frauenheilkunde, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Evaluation of two different analytical methods for circulating tumor cell detection in peripheral blood of patients with primary breast cancer.BioMed research international · 2014Trial
- Role of Circulating Tumor Cells in Determining Prognosis in Metastatic Breast Cancer.South Asian journal of cancer · 2023Article
- Herceptin-Mediated Cardiotoxicity: Assessment by Cardiovascular Magnetic Resonance.Cardiology research and practice · 2022Review
- Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.Journal of cancer research and clinical oncology · 2015Article
- Trastuzumab Administration in Patients with Metastatic Breast Cancer - Experience of a Large University Breast Center.Geburtshilfe und Frauenheilkunde · 2014Article
- Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patients.BioMed research international · 2014Review
- Guideline concordant therapy prolongs survival in HER2-positive breast cancer patients: results from a large population-based cohort of a cancer registry.BioMed research international · 2014Article
- Can ki-67 play a role in prediction of breast cancer patients' response to neoadjuvant chemotherapy?BioMed research international · 2014Article
- Expression of neuroendocrine markers in different molecular subtypes of breast carcinoma.BioMed research international · 2014Article
- Breast Cancer Risk - From Genetics to Molecular Understanding of Pathogenesis.Geburtshilfe und Frauenheilkunde · 2013Article
- Upper Blepharoplasty for Areola Reconstruction.Geburtshilfe und Frauenheilkunde · 2013Article
- Participation in the SUCCESS-A Trial Improves Intensity and Quality of Care for Patients with Primary Breast Cancer.Geburtshilfe und Frauenheilkunde · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in research have a highly influential role to play in the strategy of early detection, treatment and aftercare of breast cancer and therefore everyday clinical practice. Newly-defined prognosis factors and a new form of molecular subtype classification, for example, are intended to help identify patients who will actually benefit from chemotherapy. In the field of neoadjuvant chemotherapy, the inclusion of the angiogenesis inhibitor Bevacizumab and dual antiHER2 therapy is being discussed. What's more, where defined criteria are met, even with positive sentinel lymph nodes, axillary dissection is not performed; besides bisphosphonates RANKL antibody Denosumab is now an option in the treatment of bone metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.